Stem cell therapy for COVID-19 lung damage trial pulled before it began

NCT ID NCT05491681

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study aimed to test whether infusing donor stem cells could help people recover from acute respiratory distress syndrome (ARDS) caused by COVID-19. The trial was withdrawn before enrolling any participants, so no results are available. The approach was based on earlier lab and animal studies suggesting stem cells might reduce lung inflammation and promote healing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

allogeneic bone marrow-derived mesenchymal stem cells (MSCs)

What this could lead to

If successful, this approach could point toward a treatment to help people recover from severe lung damage caused by COVID-19.

What could go wrong

This trial was withdrawn before enrolling any participants, so no data exist. Early-phase stem cell studies often fail to show benefit or may have unexpected side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS, HUMAN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.